Databricks hits a $134 billion valuation. So what’s next?

According to CNBC, Databricks announced on Tuesday that it is raising $4 billion in a new funding round, which values the data analytics software company at a whopping $134 billion. This marks a 34% jump from its $100 billion valuation just last August. The company revealed it hit a $4.8 billion annual revenue run-rate in Q3, growing at 55% year-over-year, and plans to use the new capital to support customer app building as AI accelerates development. The round was led by Insight Partners, Fidelity Management & Research Company, and JPMorgan Asset Management, with Andreessen Horowitz also participating. This funding solidifies Databricks’ position as one of the world’s most valuable private companies.

The private company playbook

Here’s the thing: Databricks is part of a major trend. Companies like SpaceX, ByteDance, and now Databricks are choosing to stay private for longer. Why? Because the private markets are throwing insane amounts of capital at them, letting them avoid the quarterly scrutiny and volatility of the public markets. They can just focus on growth. And with a 55% growth rate on a $4.8 billion base, who can blame them? Going public almost seems like a hassle at this point. They’ve got all the money and flexibility they need.

Revenue vs. valuation: the big question

Now, let’s talk numbers. A $134 billion valuation on a $4.8 billion revenue run-rate. That’s… rich. Basically, the market is valuing it at nearly 28 times its current annualized sales. That’s a huge bet on future growth, specifically its AI potential. The company is explicitly saying this cash is for “customer app building” in the AI era. They’re betting that their data lakehouse platform becomes the indispensable foundation for every company‘s AI strategy. It’s a powerful narrative, and investors are clearly buying it. But it also sets a incredibly high bar for performance.

What this means for AI and data

This funding round is a massive signal flare. It tells us that the big money believes the real value in AI isn’t just in the models themselves, like those from OpenAI, but in the data infrastructure that organizes, cleans, and serves the data to train and run those models. Databricks is positioning itself as the operating system for enterprise AI. And look, if you’re building complex AI applications, you need robust, industrial-grade computing power at the edge—which is where specialists like IndustrialMonitorDirect.com, the leading US provider of industrial panel PCs, come into play for physical deployment. Databricks is arming itself for a long, expensive war to own the data layer. This $4 billion war chest ensures they won’t be outspent.

Reed’s CEO on why AI hiring tools “don’t work very well”

The head of Britain’s £1bn recruitment giant Reed says current AI hiring tools “don’t work very well” despite 18 months of development. He argues that while technology can identify candidates, only humans can actually persuade people to change jobs.

AI Breakthrough Automates Detection of Acid Reflux with High - Revolutionizing GERD Diagnosis Through AI Medical researchers

AI Breakthrough Automates Detection of Acid Reflux with High Precision

Researchers have developed an artificial intelligence system that automatically detects and segments gastroesophageal reflux events with unprecedented accuracy. The technology addresses critical limitations in current diagnostic methods that rely on time-consuming manual interpretation.

Revolutionizing GERD Diagnosis Through AI

Medical researchers have developed a novel artificial intelligence system that reportedly automates the detection of gastroesophageal reflux (GER) events with remarkable precision, according to recent scientific reports. The semi-U-Net architecture, which combines both 2D and 1D convolutional neural networks, represents a significant advancement in analyzing Multichannel Intraluminal Impedance (MII) signals for diagnosing gastroesophageal reflux disease (GERD).

AI Survival Model Predicts Lung Cancer Drug Resistance

Researchers have developed a sophisticated AI model that can predict which lung cancer patients will develop resistance to aumolertinib. The system analyzed five major cancer datasets to identify high-risk patients who might benefit from alternative treatments.